Diffuse large B-cell lymphoma: One or more entities? Present controversies and possible tools for its subclassification

Stefano A. Pileri, S. Dirnhofer, Ph Went, S. Ascani, E. Sabattini, T. Marafioti, A. Tzankov, L. Leoncini, B. Falini, P. L. Zinzani

Research output: Contribution to journalArticle

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the commonest type of lymphoid tumour world-wide. This category was included both in the REAL and WHO Classification aiming to lump together all malignant lymphomas characterized by the large size of the neoplastic cells, B-cell derivation, aggressive clinical presentation, and the need for highly effective chemotherapy regimens. These tumours are detected as primary or secondary forms both at the nodal and extranodal levels, in immunocompetent hosts as well as in patients with different types of immunosuppression. They display a significant variability in terms of cell morphology and clinical findings, which justifies the identification of variants and subtypes. Among the latter, the primary mediastinal one does actually correspond to a distinct clinicopathological entity. Immunophenotypic, tissue microarray and molecular studies underline the extreme heterogeneity of DLBCLs and suggest a subclassification of the tumour, based on the identification of different pathogenic pathways, which might have much greater relevance than pure morphology for precise prognostic previsions and adoption of ad hoc therapies. The more recent acquisitions on the pathobiology of DLBCLs are reviewed in the light of the authors' experience, aiming to contribute to the existing debate on the topic.

Original languageEnglish
Pages (from-to)482-509
Number of pages28
JournalHistopathology
Volume41
Issue number6
DOIs
Publication statusPublished - Dec 1 2002

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Neoplasms
Cell Size
Immunosuppression
Lymphoma
B-Lymphocytes
Drug Therapy
Therapeutics

Keywords

  • Clinics
  • Cytogenetics
  • Diffuse large B-cell lymphoma
  • Gene expression profiling
  • Genotype
  • Morphology
  • Phenotype
  • Tissue microarray

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Cell Biology

Cite this

Diffuse large B-cell lymphoma : One or more entities? Present controversies and possible tools for its subclassification. / Pileri, Stefano A.; Dirnhofer, S.; Went, Ph; Ascani, S.; Sabattini, E.; Marafioti, T.; Tzankov, A.; Leoncini, L.; Falini, B.; Zinzani, P. L.

In: Histopathology, Vol. 41, No. 6, 01.12.2002, p. 482-509.

Research output: Contribution to journalArticle

Pileri, SA, Dirnhofer, S, Went, P, Ascani, S, Sabattini, E, Marafioti, T, Tzankov, A, Leoncini, L, Falini, B & Zinzani, PL 2002, 'Diffuse large B-cell lymphoma: One or more entities? Present controversies and possible tools for its subclassification', Histopathology, vol. 41, no. 6, pp. 482-509. https://doi.org/10.1046/j.1365-2559.2002.01538.x
Pileri, Stefano A. ; Dirnhofer, S. ; Went, Ph ; Ascani, S. ; Sabattini, E. ; Marafioti, T. ; Tzankov, A. ; Leoncini, L. ; Falini, B. ; Zinzani, P. L. / Diffuse large B-cell lymphoma : One or more entities? Present controversies and possible tools for its subclassification. In: Histopathology. 2002 ; Vol. 41, No. 6. pp. 482-509.
@article{cd32add55f324928b7f01c026a285661,
title = "Diffuse large B-cell lymphoma: One or more entities? Present controversies and possible tools for its subclassification",
abstract = "Diffuse large B-cell lymphoma (DLBCL) is the commonest type of lymphoid tumour world-wide. This category was included both in the REAL and WHO Classification aiming to lump together all malignant lymphomas characterized by the large size of the neoplastic cells, B-cell derivation, aggressive clinical presentation, and the need for highly effective chemotherapy regimens. These tumours are detected as primary or secondary forms both at the nodal and extranodal levels, in immunocompetent hosts as well as in patients with different types of immunosuppression. They display a significant variability in terms of cell morphology and clinical findings, which justifies the identification of variants and subtypes. Among the latter, the primary mediastinal one does actually correspond to a distinct clinicopathological entity. Immunophenotypic, tissue microarray and molecular studies underline the extreme heterogeneity of DLBCLs and suggest a subclassification of the tumour, based on the identification of different pathogenic pathways, which might have much greater relevance than pure morphology for precise prognostic previsions and adoption of ad hoc therapies. The more recent acquisitions on the pathobiology of DLBCLs are reviewed in the light of the authors' experience, aiming to contribute to the existing debate on the topic.",
keywords = "Clinics, Cytogenetics, Diffuse large B-cell lymphoma, Gene expression profiling, Genotype, Morphology, Phenotype, Tissue microarray",
author = "Pileri, {Stefano A.} and S. Dirnhofer and Ph Went and S. Ascani and E. Sabattini and T. Marafioti and A. Tzankov and L. Leoncini and B. Falini and Zinzani, {P. L.}",
year = "2002",
month = "12",
day = "1",
doi = "10.1046/j.1365-2559.2002.01538.x",
language = "English",
volume = "41",
pages = "482--509",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Diffuse large B-cell lymphoma

T2 - One or more entities? Present controversies and possible tools for its subclassification

AU - Pileri, Stefano A.

AU - Dirnhofer, S.

AU - Went, Ph

AU - Ascani, S.

AU - Sabattini, E.

AU - Marafioti, T.

AU - Tzankov, A.

AU - Leoncini, L.

AU - Falini, B.

AU - Zinzani, P. L.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Diffuse large B-cell lymphoma (DLBCL) is the commonest type of lymphoid tumour world-wide. This category was included both in the REAL and WHO Classification aiming to lump together all malignant lymphomas characterized by the large size of the neoplastic cells, B-cell derivation, aggressive clinical presentation, and the need for highly effective chemotherapy regimens. These tumours are detected as primary or secondary forms both at the nodal and extranodal levels, in immunocompetent hosts as well as in patients with different types of immunosuppression. They display a significant variability in terms of cell morphology and clinical findings, which justifies the identification of variants and subtypes. Among the latter, the primary mediastinal one does actually correspond to a distinct clinicopathological entity. Immunophenotypic, tissue microarray and molecular studies underline the extreme heterogeneity of DLBCLs and suggest a subclassification of the tumour, based on the identification of different pathogenic pathways, which might have much greater relevance than pure morphology for precise prognostic previsions and adoption of ad hoc therapies. The more recent acquisitions on the pathobiology of DLBCLs are reviewed in the light of the authors' experience, aiming to contribute to the existing debate on the topic.

AB - Diffuse large B-cell lymphoma (DLBCL) is the commonest type of lymphoid tumour world-wide. This category was included both in the REAL and WHO Classification aiming to lump together all malignant lymphomas characterized by the large size of the neoplastic cells, B-cell derivation, aggressive clinical presentation, and the need for highly effective chemotherapy regimens. These tumours are detected as primary or secondary forms both at the nodal and extranodal levels, in immunocompetent hosts as well as in patients with different types of immunosuppression. They display a significant variability in terms of cell morphology and clinical findings, which justifies the identification of variants and subtypes. Among the latter, the primary mediastinal one does actually correspond to a distinct clinicopathological entity. Immunophenotypic, tissue microarray and molecular studies underline the extreme heterogeneity of DLBCLs and suggest a subclassification of the tumour, based on the identification of different pathogenic pathways, which might have much greater relevance than pure morphology for precise prognostic previsions and adoption of ad hoc therapies. The more recent acquisitions on the pathobiology of DLBCLs are reviewed in the light of the authors' experience, aiming to contribute to the existing debate on the topic.

KW - Clinics

KW - Cytogenetics

KW - Diffuse large B-cell lymphoma

KW - Gene expression profiling

KW - Genotype

KW - Morphology

KW - Phenotype

KW - Tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=0037636584&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037636584&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2559.2002.01538.x

DO - 10.1046/j.1365-2559.2002.01538.x

M3 - Article

C2 - 12460202

AN - SCOPUS:0037636584

VL - 41

SP - 482

EP - 509

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 6

ER -